Dr. Shahla Shahbazi | Life Sciences | Best Researcher Award
kerman university of medical sciences | Iran
Dr. Shahla Shahbazi, an accomplished Iranian scientist, is a dedicated researcher at the Infectious Diseases Research Center, Health Policy and Promotion Institute, Kermanshah University of Medical Sciences. Her career is built on deep expertise in medical microbiology, bacteriology, and infectious disease research. With extensive experience in vaccine design, molecular epidemiology, and antimicrobial resistance studies, she has contributed to peer-reviewed publications, authored books, and actively participated in national and international scientific congresses. She has also served as a reviewer for numerous respected journals and contributed to academic training, highlighting her role in advancing both research and education. Dr. Shahbazi has collaborated in multidisciplinary projects focusing on bacterial pathogenesis, nanotechnology-based vaccines, and phage therapy, positioning herself at the forefront of innovative solutions against antibiotic-resistant pathogens. Her work reflects a commitment to improving public health and advancing medical science through rigorous research, mentorship, and scientific leadership.
Profile:
Google Scholar
Education:
Dr. Shahla Shahbazi academic journey began with a Bachelor of Science in Microbiology from Alzahra University, which laid the foundation for her strong interest in infectious disease biology and laboratory research. She further advanced her academic training by pursuing a Master’s degree in Medical Microbiology at the Pasteur Institute of Iran, where her research focused on the distribution of extended-spectrum β-lactamase, quinolone, and carbapenem resistance genes in Escherichia coli. Building on her passion for understanding antimicrobial resistance, she went on to complete her PhD in Medical Bacteriology at the Pasteur Institute of Iran, where her thesis centered on designing and fabricating a vaccine candidate based on OmpA from Klebsiella pneumoniae encapsulated in silk/alginate-based nanoadjuvants for pneumonia prevention. Her academic path not only highlights her expertise in microbiology and bacteriology but also reflects her commitment to integrating molecular biology, immunology, and biotechnology to tackle pressing challenges in infectious disease research and vaccine development.
Experience:
Dr. Shahla Shahbazi has accumulated rich experience through her roles as a researcher, educator, and scientific contributor in medical microbiology and infectious diseases. At the Infectious Diseases Research Center, Kermanshah University of Medical Sciences, she has been actively engaged in pioneering projects on antimicrobial resistance, vaccine development, and nanoparticle-based therapeutics. She has also served as an executive member and reviewer in international congresses, demonstrating her influence within the scientific community. Her expertise extends beyond research, as she has contributed to teaching specialized courses, including oral health, biosafety regulations, reverse vaccinology, probiotics, and the role of AI in antimicrobial resistance. Dr. Shahbazi has also mentored postgraduate students as a thesis advisor, guiding research on carbapenem-resistant bacteria, parasitology, and emerging infections. Her publication record, editorial contributions, and involvement in global collaborations underscore her role as a dynamic scientist who bridges research, innovation, and teaching while advancing healthcare solutions through interdisciplinary approaches.
Awards and Honors:
Throughout her academic and professional journey, Dr. Shahla Shahbazi has been recognized for her excellence and contributions to science. She graduated as the top student in her Master of Science program at the prestigious Pasteur Institute of Iran, a recognition of her outstanding academic performance and research dedication. Her scientific contributions have earned her invitations to present her work at major national and international congresses, where she has shared innovative findings on antimicrobial resistance, vaccine design, and phage therapy. As a corresponding author and lead researcher on several high-impact studies, her expertise has been acknowledged by peers in her field. Beyond academic achievements, she has actively contributed to national service through her role as a reviewer for top journals, including BMC Microbiology, Journal of Basic Microbiology, and Industrial Biotechnology. These distinctions, combined with her leadership roles in scientific congresses, highlight her status as a rising figure in microbiology and medical research.
Research Focus:
Dr. Shahla Shahbazi research focuses on addressing global challenges in infectious diseases through innovative approaches in microbiology, molecular biology, and immunology. Her primary interest lies in vaccine design against multidrug-resistant bacterial pathogens, particularly Klebsiella pneumoniae and Acinetobacter baumannii, using advanced nanotechnology-based delivery systems. She also explores molecular epidemiology by studying phenotypic and genotypic markers of bacterial infections to track resistance mechanisms and virulence factors. Her work in bioinformatics and reverse vaccinology enables the identification of novel immunogenic targets for therapeutic development. Additionally, Dr. Shahbazi has contributed significantly to the exploration of phage and endolysin therapies as alternatives to antibiotics in combating resistant bacteria. Her projects also extend to green nanotechnology, utilizing plant-derived nanoparticles with antimicrobial properties. By integrating molecular biology, biotechnology, and clinical applications, her research not only advances scientific understanding but also provides practical solutions to tackle the urgent issue of antimicrobial resistance and improve public health outcomes.
Publication:
Title: Distribution of extended-spectrum β-lactam, quinolone and carbapenem resistance genes, and genetic diversity among uropathogenic Escherichia coli isolates in Tehran, Iran
Year: 2018
Citation: 83
Title: The Challenge of Global Emergence of Novel Colistin-Resistant Escherichia coli ST131
Year: 2021
Citation: 45
Title: Evaluation of multidrug efflux pump expression in clinical isolates of Staphylococcus aureus
Year: 2020
Citation: 27
Title: Zinc oxide nanoparticles impact the expression of the genes involved in toxin–antitoxin systems in multidrug‐resistant Acinetobacter baumannii
Year: 2023
Citation: 22
Title: Time-variable expression levels of mazF, atlE, sdrH, and bap genes during biofilm formation in Staphylococcus epidermidis
Year: 2019
Citation: 21
Title: Detection of ESBL and AmpC producing Klebsiella pneumoniae ST11 and ST147 from urinary tract infections in Iran
Year: 2022
Citation: 19
Title: Identification of novel putative immunogenic targets and construction of a multi-epitope vaccine against multidrug-resistant Corynebacterium jeikeium using reverse vaccinology
Year: 2022
Citation: 18
Title: Design and fabrication of a vaccine candidate based on rOmpA from Klebsiella pneumoniae encapsulated in silk fibroin-sodium alginate nanoparticles against pneumonia infection
Year: 2023
Citation: 17
Title: Evaluation of the prevalence of broad-spectrum beta-lactamases (ESBLS) and carbapenemase genes in Klebsiella pneumoniae strains isolated from burn wounds
Year: 2019
Citation: 16
Title: Polydopamine-based nano adjuvant as a promising vaccine carrier induces significant immune responses against Acinetobacter baumannii-associated pneumonia
Year: 2024
Citation: 15
Conclusion:
Dr. Shahla Shahbazi has established herself as a dedicated and innovative researcher in microbiology and infectious diseases, with a strong emphasis on antimicrobial resistance and vaccine development. Her achievements in publications, research projects, teaching contributions, and scientific service make her highly suitable for the Research for Best Researcher Award. With further expansion into global collaborations and translational applications, she has the potential to significantly advance scientific knowledge and strengthen her leadership role in the international research community.